EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study

Onyema Ogbuagu, Aditya Gaur, James H McMahon, Linda Gorgos, Javier O Morales-Ramirez, Kimberly Workowski, Jason Brunetta, Kwad Mponponsuo, Sean E Collins, Laurie A VanderVeen, Nan Zhang, Hailin Huang und 2 weitere

The Lancet Microbe · 2026-03 · 7 (3) · 101283

DOI: 10.1016/j.lanmic.2025.101283 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Lancet Microbe, 2026-03. Verfasst von Onyema Ogbuagu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: onyema.ogbuagu@yale.edu. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Quinolones. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In a phase 1b study (NCT04811040), lenacapavir combined with the broadly neutralising antibodies (bNAbs) teropavimab and zinlirvimab maintained virological suppression (HIV-1 RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsQuinolonesHumansFemaleHIV-1MaleTreatment OutcomeAdultMiddle AgedViral LoadAustraliaAntibodies, NeutralizingCanadaAcetamidesIndazoles

Substanzen

Anti-HIV AgentsQuinolonesAntibodies, NeutralizinglenacapavirAcetamidesIndazoles

Autor:innen und Institutionen

  • Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: onyema.ogbuagu@yale.edu.
  • St Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Infectious Diseases, Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
  • AXCES Research Group, Santa Fe, NM, USA.
  • Clinical Research Puerto Rico, San Juan, Puerto Rico.
  • Department of Medicine, Emory University, Atlanta, GA, USA.

Förderung

  • Gilead Sciences Inc

Zitieren

APA

Ogbuagu, O., Gaur, A., McMahon, J. H., Gorgos, L., Morales-Ramirez, J. O., Workowski, K., Brunetta, J., Mponponsuo, K., Collins, S. E., VanderVeen, L. A., Zhang, N., Huang, H., Baeten, J. M., & Eron, J. (2026). Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. The Lancet Microbe, 7(3), 101283. https://doi.org/10.1016/j.lanmic.2025.101283

Vancouver

Ogbuagu O, Gaur A, McMahon JH, Gorgos L, Morales-Ramirez JO, Workowski K, et al. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. The Lancet Microbe. 2026;7(3):101283. doi:10.1016/j.lanmic.2025.101283

BibTeX
@article{Ogbuagu2026,
  author = {Ogbuagu, Onyema and Gaur, Aditya and McMahon, James H and Gorgos, Linda and Morales-Ramirez, Javier O and Workowski, Kimberly and Brunetta, Jason and Mponponsuo, Kwad and Collins, Sean E and VanderVeen, Laurie A and Zhang, Nan and Huang, Hailin and Baeten, Jared M and Eron, Joseph},
  title = {Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study},
  journal = {The Lancet Microbe},
  year = {2026},
  volume = {7},
  number = {3},
  pages = {101283},
  doi = {10.1016/j.lanmic.2025.101283}
}
Kostenlos starten →